Margot Goodkin, MD, Ph.D. (l) and Bilal Khan, MBA.

ALISO VIEJO, Calif.—SpyGlass Pharma, a privately-held ophthalmic biotechnology company, today announced the appointments of Margot Goodkin, MD, Ph.D., as chief medical officer and Bilal Khan, MBA, to the SpyGlass board of directors. Dr. Goodkin and Khan each bring a wealth of experience to support the growth and continued development of the SpyGlass intraocular drug delivery platform. The company is focused on the development of the world’s first, IOL-mounted, controlled release drug delivery platform capable of delivering multiple years of therapy.

Dr. Goodkin is a glaucoma fellowship-trained ophthalmologist and a biopharmaceutical industry veteran. Prior to joining SpyGlass, Dr. Goodkin was executive director, ophthalmology clinical development at Allergan/AbbVie, where she successfully helped develop Durysta, the first intracameral sustained-release therapy approved in the U.S. to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

She also previously worked at the U.S. Food and Drug Administration’s Center for Devices and Radiologic Health, where she evaluated and approved clinical trials investigating ophthalmic devices.

“Dr. Goodkin’s deep expertise in ophthalmic clinical development and regulatory proceedings make her uniquely qualified to lead our clinical program,” said Patrick Mooney, CEO of SpyGlass Pharma. “Dr. Goodkin’s extensive leadership experience and personal conviction to improve patient care will enhance this company’s dedicated leadership team. We look forward to partnering together as we progress our promising SpyGlass platform through the FDA approval process.”

Khan, who joins the SpyGlass board of directors, is currently the chief executive officer of New World Medical. In this role, Khan successfully led multiple product launches in the glaucoma market, including KDB Glide, the Ahmed ClearPath drainage devices, and, most recently, the Streamline Surgical System. Khan is well suited to provide guidance relating to the growth and future commercialization of the SpyGlass platform, given his financial background and deep knowledge of the glaucoma commercial and operational landscape.

“We are thrilled to welcome Bilal to the SpyGlass board of directors. Bilal’s experience will be vital to the continued growth and success of this company,” said Dr. Malik Y. Kahook, executive chair, president and co-founder of SpyGlass Pharma.

SpyGlass recently initiated a Phase I/II study to investigate the safety and efficacy of its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.